What Domainex does

Domainex Limited is a UK-based, privately held Contract Research Organization (CRO) founded in 2001 and headquartered at Chesterford Research Park near Cambridge, providing fully integrated small-molecule drug discovery services to pharmaceutical companies, biotechnology firms, and academic research groups globally. Its service portfolio spans the full pre-clinical continuum — target validation, hit identification, hit-to-lead, lead optimisation, and pre-clinical candidate nomination — across target classes including GPCRs, ion channels, kinases, methyltransferases, proteases, and protein-protein interactions, with therapeutic area focus in oncology, inflammation, CNS, and anti-infectives.

The company is differentiated by a set of proprietary technology platforms: PureDisc™ (a polymer-encapsulated nanodisc approach for stabilising membrane proteins in native lipid environments), LeadBuilder (a virtual screening platform for hit identification), Combinatorial Domain Hunting / CDH (a patented method for expressing difficult protein targets as soluble fragments), and Direct-to-Biology / D2B (an accelerated protein-to-assay workflow). These are complemented by biophysical capabilities such as Spectral Shift, MST, Cryo-EM, and X-ray crystallography. Domainex also recently added biotherapeutics expression and RNA services, and in 2024 became the first CRO to install Nuclera's eProtein Discovery benchtop system.

Domainex generates revenue through fee-for-service contract research engagements priced on a project-by-project basis, using a direct enterprise field-sales model with personalised, collaborative engagement. The customer base is segmented horizontally across large pharma, emerging biotech, and academic translational groups. Indirect signals of commercial traction include an 80% repeat-customer rate, a 95% customer recommendation rate, multiple peer-reviewed publications in high-impact journals (including Nature Communications), named inventors on numerous patents, and collaborations on Wellcome Trust-funded programmes progressing to pre-clinical candidate nomination.

Name

Domainex

Legal name

Domainex Limited

Website

https://domainex.co.uk

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

11–50 employees

Short description

Domainex is a UK-based, privately held integrated drug discovery CRO providing small-molecule services from target validation to pre-clinical candidate nomination to pharma, biotech, and academic clients, anchored by proprietary platforms PureDisc, LeadBuilder, and Combinatorial Domain Hunting.

Ownership category

akta.pro rank

Product category

Drug Discovery CRO Services

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)

akta.pro primary industry

Global Health Research, Clinical Trials & Product Development Partnerships (PDPs) (HLAJAOAM)

Keywords

• Drug discovery CRO
• Medicinal chemistry services
• Preclinical research services
• Biophysical assay services
• Contract research organization

Headquarters

HQ city

Cambridge

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Contract Research Services: Domainex provides fee-for-service drug discovery research services on a contract basis, offering integrated capabilities from target identification through to pre-clinical candidate nomination. Services are delivered to pharmaceutical companies, biotechnology firms, and academic groups globally on a project-by-project basis, with expertise across multiple therapeutic areas and target classes.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Domainex is a contract research organization that provides fully integrated small-molecule drug discovery services for pharmaceutical, biotechnology, and academic clients worldwide. Its core service covers the entire pre-clinical pipeline from target validation through hit identification, hit-to-lead, lead optimization, and pre-clinical candidate nomination, supported by proprietary platforms for membrane protein production, virtual screening, and difficult-target expression.

Product overview

Domainex is an integrated drug discovery CRO providing comprehensive small-molecule drug discovery services from target validation to preclinical candidate nomination. The company's service portfolio centers on proprietary technology platforms including PureDisc™ for membrane protein production, LeadBuilder for virtual screening, Combinatorial Domain Hunting for difficult targets, and Direct-to-Biology for accelerated hit finding. These core technologies are deployed across integrated service offerings spanning biosciences (assay development, biochemistry, cellular biology, biophysics, structural biology including Cryo-EM and X-ray crystallography), medicinal and synthetic chemistry, computational chemistry, fragment-based and high-throughput screening, ADME/DMPK services, and dedicated expertise in target classes such as GPCRs, ion channels, kinases, proteases, and protein-protein interactions. The company operates across therapeutic areas including oncology, inflammation, CNS, and anti-infectives.

Differentiator

Problem solved

Functional benefit

Products and services

• Integrated Drug Discovery Services End-to-end small-molecule drug discovery service for pharmaceutical, biotechnology, and academic clients, covering the full pre-clinical pipeline from target validation through to pre-clinical candidate nomination, delivered by an in-house multidisciplinary team.
• PureDisc™ Enabled Membrane Protein Production Detergent-free membrane protein production service using polymer-encapsulated nanodiscs (PoLiPa) to purify and stabilize membrane proteins — including GPCRs, ion channels, and solute carriers — in their natural lipid composition for biochemical, biophysical, and structural studies.
• LeadBuilder Virtual Screening Proprietary virtual screening service platform that enables rapid and cost-effective access to high-quality chemical hits for hit identification and lead generation, particularly suited for translational research and emerging biotech programs.
• Combinatorial Domain Hunting (CDH) Patented protein expression service for difficult-to-express targets that identifies soluble protein fragments suitable for structural biology, biophysics, and bioassay applications.
• Direct-to-Biology (D2B) Accelerated hit-finding service that progresses from gene to assay-ready protein without traditional purification steps, enabling faster iteration in lead discovery programs.
• Spectral Shift and MST Services Biophysical screening service that measures ligand-biomolecule interactions directly in solution using Spectral Shift, MicroScale Thermophoresis (MST), and Temperature Related Intensity Change (TRIC) technologies — enabling direct binding measurement, fragment screening, and KD determination from nanomolar to millimolar affinities.

Quantifiable outcome

• Reduced drug discovery timelines by up to 30% compared to industry averages through integrated service model
• +5 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability3 records

Feature6 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• PharmaceleracoreStrategic or Co-development Partner · 27 August 2025Domainex and Pharmacelera entered a strategic collaboration to accelerate drug discovery for transmembrane proteins such as GPCRs and ion channels. The partnership combines Domainex's stabilisation and high-throughput platforms with Pharmacelera's AI-driven molecular modelling tools to address key therapeutic targets that pose significant development challenges.
• NucleracoreTechnology or Integration · 8 November 2024Domainex became the first CRO to install Nuclera's eProtein Discovery benchtop system, enabling accelerated integration of antibody expression and binding validation capabilities. This installation marks Domainex's first CRO implementation of the eProtein Discovery technology.
• Queen's University BelfastcoreStrategic or Co-development Partner · 17 April 2015Longstanding collaboration between Domainex and Queen’s University Belfast to discover and develop first-in-class small molecule inhibitors of the FLIP-FADD protein-protein interaction for treatment of non-small cell lung carcinoma. The partnership received Wellcome Trust Seeding Drug Discovery funding and progressed to clinical candidate nomination stage.
• QIMR BerghofercoreStrategic or Co-development PartnerCollaboration combining QIMR Berghofer's expertise in KMT biology with Domainex's medicinal chemistry, biochemistry, biophysics, and structural biology capabilities to further characterize G9a lysine methyltransferase inhibitor leads for cancer treatment.
• University of OxfordcoreStrategic or Co-development PartnerCollaboration with Professor Terry Rabbitts' group at Oxford University to develop fragment hits into lead molecules binding to activated RAS and inhibiting RAS-effector protein interactions for cancer treatment. This work resulted in the first published study of structure-based design of direct RAS-effector inhibitors.
• St George's University London and University of ManchestercoreStrategic or Co-development PartnerCollaboration with St George's University London and University of Manchester on a drug discovery program targeting Der p 1 protease for allergic asthma treatment. The program ultimately led to successful nomination of a candidate drug for inhaled asthma treatment, funded by the Wellcome Trust.
• Wake Forest Medical SchoolminorStrategic or Co-development PartnerCollaboration with Professor Fred Perino at Wake Forest Medical School demonstrating that DMXD-011 reduced expression of Interferon Stimulated Genes in TREX-1 D18N mutant mice model of familial chilblain lupus, supporting the pre-clinical candidate's disease-modifying potential.
• Erasmus University RotterdamminorStrategic or Co-development PartnerCollaboration with Marjan Versnel at Erasmus University Rotterdam for ex vivo human studies examining the effect of DMXD-011 on cytokine levels in blood samples from patients with SLE, Sjogren's syndrome, and systemic sclerosis.

Scale indicators2 records

Direct peers

• Pharmaron: China-headquartered global CRO/CDMO offering fully integrated drug discovery and development services including chemistry, biology, DMPK, and pre-clinical capabilities. Direct competitor for biotech and pharma outsourcing with broader scale and lower-cost positioning.
• Reaction Biology Corp: US-based CRO providing drug discovery services including biochemical and cell-based assay services, medicinal chemistry, and biophysics. Comparable in scope to Domainex's biology and screening services with strong overlap in biochemical assay offerings.
• Concept Life Sciences: UK-based CRO providing drug discovery and analytical services including medicinal chemistry, in vitro pharmacology, and ADME. Comparable mid-sized UK CRO competing for the same European biotech and academic clients as Domainex.
• BioAscent Discovery: Scotland-based integrated drug discovery CRO offering medicinal chemistry, biology, and DMPK services with similar size and target client base to Domainex. Provides a directly comparable UK/European mid-sized CRO alternative.
• Selvita: Poland-headquartered CRO offering integrated drug discovery services spanning medicinal chemistry, in vitro biology, DMPK, and computational chemistry. Comparable mid-sized CRO with strong focus on small-molecule discovery services for biotech and pharma clients.
• Sygnature Discovery: UK-based integrated drug discovery CRO offering medicinal chemistry, biosciences, and DMPK services to pharma and biotech. Closely comparable to Domainex in size, geography (Nottingham, UK), and integrated service model; competes head-to-head for the same biotech and mid-pharma clients.

Broad incumbents

• WuXi AppTec: Global CRO/CDMO providing fully integrated drug discovery and development services across all major modalities. The dominant Asia-headquartered scale competitor in integrated discovery outsourcing, competing with Domainex primarily on large-pharma accounts and scale-driven pricing.
• Eurofins Discovery Services: Division of Eurofins Scientific offering integrated drug discovery services including in vitro ADME, pharmacology, medicinal chemistry, and bioanalysis. Significantly larger scale competitor operating globally across multiple discovery and development service lines.
• Charles River Laboratories: Global public CRO offering drug discovery and development services across multiple modalities and target classes. The dominant full-service incumbent that competes with Domainex for large-pharma integrated discovery contracts, with substantially greater scale and global footprint.
• Evotec SE: Large publicly-listed German integrated drug discovery CRO offering end-to-end services from target identification through pre-clinical and beyond. Operates at significantly larger scale than Domainex across multiple sites globally and represents the broad incumbent benchmark in integrated discovery outsourcing.

Market position

Strengths5 records

Weaknesses5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/domainex_uk
• Facebookfacebook.com/domainex
• LinkedInlinkedin.com/company/domainex

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds5 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Domainex